285 related articles for article (PubMed ID: 30859382)
21. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
22. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
[TBL] [Abstract][Full Text] [Related]
23. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
[TBL] [Abstract][Full Text] [Related]
24. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
25. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging.
Kobayashi Y; Kobayashi H; Giles JT; Hirano M; Nakajima Y; Takei M
Int J Rheum Dis; 2016 Nov; 19(11):1169-1174. PubMed ID: 26480957
[TBL] [Abstract][Full Text] [Related]
26. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis.
Kerekes G; Soltész P; Szucs G; Szamosi S; Dér H; Szabó Z; Csáthy L; Váncsa A; Szodoray P; Szegedi G; Szekanecz Z
Isr Med Assoc J; 2011 Mar; 13(3):147-52. PubMed ID: 21608334
[TBL] [Abstract][Full Text] [Related]
27. Anakinra and its rapidly expanding role in management of nonarthritic systemic disorders.
Kapoor S
J Rheumatol; 2009 Feb; 36(2):446; author reply 447. PubMed ID: 19208574
[No Abstract] [Full Text] [Related]
28. Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study.
Van Tassell BW; Lipinski MJ; Appleton D; Roberts CS; Kontos MC; Abouzaki N; Melchior R; Mueller G; Garnett J; Canada J; Carbone S; Buckley LF; Wohlford G; Kadariya D; Trankle CR; Oddi Erdle C; Sculthorpe R; Puckett L; DeWilde C; Shah K; Angiolillo DJ; Vetrovec G; Biondi-Zoccai G; Arena R; Abbate A
Clin Cardiol; 2018 Aug; 41(8):1004-1008. PubMed ID: 30033595
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis.
Wang J; Devenport J; Low JM; Yu D; Hitraya E
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):882-5. PubMed ID: 26473986
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis.
Protogerou AD; Zampeli E; Fragiadaki K; Stamatelopoulos K; Papamichael C; Sfikakis PP
Atherosclerosis; 2011 Dec; 219(2):734-6. PubMed ID: 21968316
[TBL] [Abstract][Full Text] [Related]
31. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
[TBL] [Abstract][Full Text] [Related]
32. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
[TBL] [Abstract][Full Text] [Related]
33. Comparison of atherosclerotic indicators between cardio ankle vascular index and brachial ankle pulse wave velocity.
Horinaka S; Yabe A; Yagi H; Ishimura K; Hara H; Iemua T; Matsuoka H
Angiology; 2009; 60(4):468-76. PubMed ID: 19015165
[TBL] [Abstract][Full Text] [Related]
34. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).
Van Tassell BW; Arena R; Biondi-Zoccai G; Canada JM; Oddi C; Abouzaki NA; Jahangiri A; Falcao RA; Kontos MC; Shah KB; Voelkel NF; Dinarello CA; Abbate A
Am J Cardiol; 2014 Jan; 113(2):321-327. PubMed ID: 24262762
[TBL] [Abstract][Full Text] [Related]
35. Heart Rate-corrected QT Interval Duration in Rheumatoid Arthritis and Its Reduction with Treatment with the Interleukin 6 Inhibitor Tocilizumab.
Kobayashi H; Kobayashi Y; Yokoe I; Kitamura N; Nishiwaki A; Takei M; Giles JT
J Rheumatol; 2018 Dec; 45(12):1620-1627. PubMed ID: 30173151
[TBL] [Abstract][Full Text] [Related]
36. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
37. Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis--a prospective study.
Tam LS; Shang Q; Li EK; Wong S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
Semin Arthritis Rheum; 2013 Feb; 42(4):333-45. PubMed ID: 22920235
[TBL] [Abstract][Full Text] [Related]
38. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial.
Kume K; Amano K; Yamada S; Hatta K; Ohta H; Kuwaba N
J Rheumatol; 2011 Oct; 38(10):2169-71. PubMed ID: 21807781
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
[TBL] [Abstract][Full Text] [Related]
40. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
